Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Change in Acquisitions & Divestments: 2016-2025

Historic Change in Acquisitions & Divestments for Spyre Therapeutics (SYRE) over the last 10 years, with Sep 2025 value amounting to $99.2 million.

  • Spyre Therapeutics' Change in Acquisitions & Divestments rose 27.51% to $99.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $340.0 million, marking a year-over-year increase of 68.05%. This contributed to the annual value of $246.0 million for FY2024, which is 516.46% up from last year.
  • Spyre Therapeutics' Change in Acquisitions & Divestments amounted to $99.2 million in Q3 2025, which was down 7.18% from $106.9 million recorded in Q2 2025.
  • Spyre Therapeutics' Change in Acquisitions & Divestments' 5-year high stood at $106.9 million during Q2 2025, with a 5-year trough of $3.2 million in Q2 2023.
  • Moreover, its 3-year median value for Change in Acquisitions & Divestments was $60.2 million (2024), whereas its average is $56.3 million.
  • As far as peak fluctuations go, Spyre Therapeutics' Change in Acquisitions & Divestments plummeted by 87.00% in 2023, and later spiked by 1,680.80% in 2024.
  • Spyre Therapeutics' Change in Acquisitions & Divestments (Quarterly) stood at $22.9 million in 2021, then dropped by 19.26% to $18.5 million in 2022, then increased by 2.16% to $18.9 million in 2023, then skyrocketed by 230.94% to $62.5 million in 2024, then climbed by 27.51% to $99.2 million in 2025.
  • Its Change in Acquisitions & Divestments was $99.2 million in Q3 2025, compared to $106.9 million in Q2 2025 and $71.4 million in Q1 2025.